Global CNV (Choroidal NeoVascularization) Market, By Diagnosis (Fluorescein AngiographyOptical Coherence Tomography, Others), Treatment (Anti-VEGF, Photodynamic Therapy, Thermal Laser, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
CNV (Choroidal NeoVascularization) Market Analysis and Size
Choroidal NeoVascularization (CNV) is witnessed in individuals having diabetic retinopathy. In rare cases, it can occur among individuals having defects in Bruch's membrane, which is the innermost layer of the choroid. The American Academy of Ophthalmology has also observed that patients with Choroidal NeoVascularization (CNV) in one eye have a very high probability to contract choroidal neovascularization (CNV) in the other eye within a short frame of time. Currently, the market players that manufacture Ranibizumab are Novartis (licensed) in global choroidal neovascularization (CNV) market and Genetech (patented) in the U.S.
Data Bridge Market Research analyses a growth rate in the global CNV (choroidal neovascularization) market in the forecast period 2022-2029. The expected CAGR of global CNV (choroidal neovascularization) market is tend to be around 8% in the mentioned forecast period. The market was valued at USD 5.64 million in 2021, and it would grow upto USD 10.44 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
CNV (Choroidal NeoVascularization) Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Diagnosis (Fluorescein Angiography, Optical Coherence Tomography, Others), Treatment (Anti-VEGF, Photodynamic Therapy, Thermal Laser, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Regeneron Pharmaceuticals Inc (U.S.) |
|
Market Opportunities |
|
Market Definition
CNV (choroidal neovascularization) is the type of condition wherein new blood vessels initiate in the choroid. When a patient suffering from AMD produces too much vascular endothelial growth factor, and then grows in the retina. These new blood vessels look normal but they are leaky and allow fluid from the blood. When fluid or red blood cells enter the retina, it immediately alters the vision because it forms a “blister” in the retina, which is normally flat.
Global CNV (Choroidal NeoVascularization) Market Dynamics
Drivers
- Increased Drug Development
There are many drugs that are getting developed which are helping in growing the market growth. Presently the companies that manufacture Ranibizumab are Novartis (licensed) in global choroidal neovascularization (CNV) market and Genetech in the U.S. Bevacizumab too was developed by Roche Pharma in association with Genentech and is currently marketed by Roche internationally. Pegaptanib is manufactured by Eyetch Inc. and marketed by Pfizer Inc.
- Growing Demand for Hospitals and Clinics
The demand for hospitals and clinics are rising high due to the rising number of the piriformis syndrome patients which increases the number of treatments in the hospitals & clinics. This is the primary driver expected to boost the market's growth during the forecast period.
Opportunities
- Higher Cases of Age-related macular degeneration
As per the reports of the British Journal of Ophthalmology published in 2007, age-related macular degeneration (AMD) is one of the top causes of irreversible sight loss among adults registered as legally blind. In 2007, almost 250,000 people were suffering from neovascular AMD in the U.K, with an occurrence rate of 25,000 and 30,000 new cases annually. All these factors are also contributing in the growth of the market.
- The Wide Application of Generic Drugs
Branded drug manufacturers and generic producing firms are joining up together for the production of generic drugs after patent expiry, which is projected to lift the growth of generics. In addition, major firms are gradually focusing on developing generics due to the increase in off-patented drugs in the market. Although, marketing exclusivity given by the FDA to patent holders for several indications is predicted to hamper market growth to a slight extent.
Restraints/Challenges
- Treatment Associated Complications
There are several treatment associated complications that are hampering the market growth. Complications such as intestinal gas distension associated with argon flow, which can leave the patient feeling discomfort after the endoscopic session, hampering the market growth.
- Unavailability of Appropriate Treatments
To treat conditions that are rare, many times, all treatments are not available, especially in the under-developed countries. The severe patients needs to be treated with advanced techniques but at times, these are not available in hospitals and clinics. Thus, it hampers the market growth.
This global CNV (choroidal neovascularization) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global CNV (choroidal neovascularization) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global CNV (Choroidal NeoVascularization) Market Scope
The global Gastric Antral Vascular Ectasia (GAVE) treatment market is segmented on the basis of treatment, diagnosis, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Fluorescein Angiography
- Optical Coherence Tomography
- Others
Treatment
- Anti-VEGF
- Photodynamic Therapy
- Thermal Laser
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
CNV (Choroidal NeoVascularization) Market Regional Analysis/Insights
The global CNV (choroidal neovascularization) market is analyzed and market size insights and trends are provided by treatment, diagnosis, end-user, distribution channel as referenced above.
The major countries covered in the global CNV (choroidal neovascularization) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period because of the increasing investments by hospitals to purchase new endoscopic equipment and rising research activities to enhance endoscopy.
Asia-Pacific is dominating the market due to the presence of key generic pharmaceuticals companies in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global CNV (Choroidal NeoVascularization) Market Share Analysis
The global CNV (choroidal neovascularization) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global CNV (choroidal neovascularization) market.
Key players operating in the global CNV (choroidal neovascularization) market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- AbbVie.Inc (Ireland)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Regeneron Pharmaceuticals Inc (U.S.)
SKU-
